626 related articles for article (PubMed ID: 26408738)
1. Hematogenous Splenic Metastases as an Independent Negative Prognosis Factor at the Moment of Primary Cytoreduction in Advanced Stage Epithelial Ovarian Cancer--A Single Center Experience.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Oct; 35(10):5649-54. PubMed ID: 26408738
[TBL] [Abstract][Full Text] [Related]
2. Splenectomy as Part of Cytoreductive Surgery in Recurrent Epithelial Ovarian Cancer.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Sep; 35(9):5097-101. PubMed ID: 26254413
[TBL] [Abstract][Full Text] [Related]
3. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit.
Bacalbasa N; Dima S; Brasoveanu V; David L; Balescu I; Purnichescu-Purtan R; Popescu I
World J Surg Oncol; 2015 Aug; 13():235. PubMed ID: 26243426
[TBL] [Abstract][Full Text] [Related]
4. Splenic hilar lymph node metastasis independently predicts poor survival for patients with gastric cancers in the upper and/or the middle third of the stomach.
Zhu GL; Sun Z; Wang ZN; Xu YY; Huang BJ; Xu Y; Zhu Z; Xu HM
J Surg Oncol; 2012 Jun; 105(8):786-92. PubMed ID: 22105768
[TBL] [Abstract][Full Text] [Related]
5. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
[TBL] [Abstract][Full Text] [Related]
6. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
[TBL] [Abstract][Full Text] [Related]
7. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
[TBL] [Abstract][Full Text] [Related]
8. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
[TBL] [Abstract][Full Text] [Related]
9. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
[TBL] [Abstract][Full Text] [Related]
10. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
11. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
12. The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.
Fang C; Zhang Y; Zhao L; Chen X; Xia L; Zhang P
BMC Cancer; 2020 Jul; 20(1):654. PubMed ID: 32660444
[TBL] [Abstract][Full Text] [Related]
13. Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
Musella A; Marchetti C; Palaia I; Perniola G; Giorgini M; Lecce F; Vertechy L; Iadarola R; De Felice F; Monti M; Muzii L; Angioli R; Panici PB
Ann Surg Oncol; 2015 Dec; 22(13):4211-6. PubMed ID: 25801357
[TBL] [Abstract][Full Text] [Related]
14. Comparison of morbidity and survival between primary and interval cytoreductive surgery in patients after modified posterior pelvic exenteration for advanced ovarian cancer.
Revaux A; Rouzier R; Ballester M; Selle F; Daraï E; Chéreau E
Int J Gynecol Cancer; 2012 Oct; 22(8):1349-54. PubMed ID: 22954783
[TBL] [Abstract][Full Text] [Related]
15. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
16. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection.
Baiocchi G; Cestari LA; Macedo MP; Oliveira RA; Fukazawa EM; Faloppa CC; Kumagai LY; Badiglian-Filho L; Menezes AN; Cunha IW; Soares FA
J Surg Oncol; 2011 Sep; 104(3):250-4. PubMed ID: 21472733
[TBL] [Abstract][Full Text] [Related]
17. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
[TBL] [Abstract][Full Text] [Related]
18. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
[TBL] [Abstract][Full Text] [Related]
19. Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers.
Raspagliesi F; Bogani G; Ditto A; Martinelli F; Chiappa V; Borghi C; Scaffa C; Morano F; Maltese G; Lorusso D
Ann Surg Oncol; 2017 Oct; 24(11):3396-3405. PubMed ID: 28795373
[TBL] [Abstract][Full Text] [Related]
20. [Splenectomy in epithelial ovarian cancer: analysis of 32 cases].
Zheng AW; Zheng F; Chen YQ; Zhu HN; Qian JH
Zhonghua Fu Chan Ke Za Zhi; 2008 Mar; 43(3):197-200. PubMed ID: 18788569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
